|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hematopoietic cell transplantation for Crohn’s disease;is it time?显示文摘AIM: To review all studies in the literature that have assessed Hematopoietic cell transplantation (HCT) and Crohn’s disease (CD) with the ultimate aims of determining if this is a viable treatment option for those with CD. A secondary aim was to review the above literature and determine if the studies shed further light on the mechanisms involved in the pathogenesis of CD. METHODS: An extensive Medline search was performed on all articles from 1970 to 2005 using the ; bone marrow transplant, stem cell, hematopoietic cell, Crohn’s disease and inflammatory bowel disease. RESULTS: We identified one case in which a patient developed CD following an allogeneic HCT from a sibling suffering with CD. Evidence for transfer of the genetic predisposition to develop CD was also identified with report of a patient that developed severe CD following an allogeneic HCT. Following HCT it was found that the donor (that had no signs or symptoms of CD) and the recipient had several haplotype mismatches in HLA class Ⅲ genes in the IBD3 locus including a polymorphism of NOD2/CARD15 that has been associated with CD. Thirty three published cases of patients with CD who underwent either autologous or allogeneic HCT were identified. At the time of publication 29 of these 33 patients were considered to be in remission. The median follow-up time was seven years, and twenty months for allogeneic and autologous HCT respectively.For patients who underwent HCT primarily for treatment of their CD there have been no mortalities related to transplant complications. CONCLUSION: Overall these preliminary data suggest that both allogeneic and autologous HCT may be effective in inducing remission in refractory CD. Thissupports the hypothesis that the hematolymphatic cells play a key role in CD and that resetting of the immune system may be a critical approach in the management or cure of CD. | Y Leung M Geddes J Storek R Panaccione PL Beck | 2006 | World Journal of Gastroenterology2006，12，41： | 5 |
| 2 | On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprineor 6-mercaptopurine intolerant IBD patients显示文摘AIM: To determine the tolerability and safety profile of a low-dose maintenance therapy with 6-TG in azathioprine (AZA) or 6-mercaptopurine (6-MP) intolerant inflammatory bowel disease (IBD) patients over a treatment period of at least 1 year.METHODS: Database analysis.RESULTS: Twenty out of ninety-five (21%) patients discontinued 6-TG (mean dose 24.6 mg; mean 6-TGN level 540 pmol/8×108 RBC) within 1 year. Reasons for discontinuation were GI complaints (31%), malaise (15%)and hepatotoxicity (15%). Hematological events occurred in three patients, one discontinued treatment. In the 6-TG-tolerant group, 9% (7/75) could be classified as hepatotoxicity. An abdominal ultrasound was performed in 54% of patients, one patient had splenomegaly.CONCLUSION: The majority of AZA or 6-MP-intolerant IBD patients (79%) is able to tolerate maintenance treatment with 6-TG (dosages between 0.3 and 0.4 mg/kg per d). 6-TG may still be considered as an escape maintenance immunosuppressant in this difficult to treat group of patients, taking into account potential toxicity and efficacy of other alternatives. The recently reported hepatotoxicity is worrisome and 6-TG should therefore be administered only in prospective trials. | Nanne KH de Boer Luc JJ Derijks Lennard PL Gilissen Daniel W Hommes Leopold GJB Engels Sybrand Y de Boer Gijsbertus den Hartog Piet M Hooymans Anja BU M(?)kelburg Barend D Westerveld Anton HJ Naber Chris JJ Mulder Dirk J de Jong | 2005 | World Journal of Gastroenterology2005，11，35： | 4 |
| 3 | Comparison of inhibitory effects of local anesthetics on immune functions of neutrophils显示文摘 | Azuma Y Shinohara M Wang PL | 2000 | Int J Immunopharmacol2000，22，10： | 1 |
| 4 | Chemotherapy- and radiotherapy- induced intestinal damage is regulated by intestinal trefoil factor显示文摘 | Beck PL Wong JF Li Y | 2004 | Gastroenterology2004，126，3： | 1 |
| 5 | T-cell coregulatory moleeule expression in urothelial cell carcinoma:clinicopathologic correlations and association with survival显示文摘 | Boorjian SA Sheinin Y Crispen PL | 2008 | Clin Cancer Res2008，14，15： | 1 |
| 6 | Inhibition of MDA-MB-231human breast tumor xenografts and HER2 expression by antitumor agents and MAP30显示文摘 | Lee-Huang S Huang PL Sun Y | 2000 | Antcancer Res2000，20，： | 1 |
| 7 | Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases 显示文摘 | Chavin G Sheinin Y Crispen PL | 2009 | Clin Cancer Res2009，15，6： | 1 |
| 8 | Lysozyme and RNases as anti-HIV components in beta-core preparations of human chorionic gonadotropin显示文摘 | Lee-Huang S Huang PL Sun Y | 1999 | Proc Natl Acad Sci USA1999，96，： | 1 |
| 9 | Chemotherapy - and radiotherapy - induced inteslinaldarnage is regulated by intestinal trefoil factor 显示文摘 | Beck PL Wong JF Li Y | 2004 | Gastroenterology2004，126，3： | 1 |
| 10 | Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma 显示文摘 | Crispen PL Sheinin Y Roth TJ | 2008 | Clin Cancer Res2008，14，16： | 1 |
| 11 | Autoantibodies as predic- tors of pregnancy complications显示文摘 | Carp HJA Meroni PL Shoenfeld Y | 2008 | Rheumatology2008，47，： | 1 |
| 12 | Population-based study on incidence, survival rates, and genetic alterations of low-grade dif- fuse astrocytomas and oligodendrogliomas 显示文摘 | Okamoto Y Di Patre PL Burkhard C | 2004 | Acta neuro-pathologi- ca2004，108，： | 1 |
| 13 | Chemotherapy-and radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor显示文摘 | Wong JF Li Y | 2004 | Gastroenterology2004，126，3： | 1 |
| 14 | Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2-breast cancer with liver metastasis in the USA显示文摘 | Lin PL Hao Y Xie J | 2015 | Expert Opin Pharmacother2015，16，14： | 1 |
| 15 | Overexpression of a dominant-negative mutant Ubc9 is associated with increased sensitivity to anticancer drugs显示文摘 | Mo YY Yu Y Ee PL | 2004 | Cancer Res2004，64，8： | 1 |
| 16 | Anti-HIV agent MAP30 modulates the expression profile of viral and cellular genes for proliferation and apoptosis in AIDS-related lymphoma cells infected with Kaposi's sarcoma-associated virus显示文摘 | Sun Y Huang PL Li JJ | 2001 | Biochem Biophy Res Commun2001，287，4： | 1 |
| 17 | Design and testing of a virtual environment to train stroke patients with unilateral spatial neglect to cross a street safely显示文摘 | Weiss PL Naveh Y Katz N | 2003 | Occup Ther Int2003，10，1： | 1 |
| 18 | Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials 显示文摘 | Nguyen PL Je Y Schutz FA | 2011 | JAMA2011，306，21： | 1 |
| 19 | Phase Ⅱ randomised trial ofchemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil inoesophageal cancer显示文摘 | Conroy T Yataghène Y Etienne PL | 2010 | British Journal of Cancer2010，18，： | 1 |
| 20 | Phosphorylation-dependent deg-radation of p300 by doxorubicin-activated p38 mitogen-activatedprotein kinase in cardiac cells 显示文摘 | Poizat C Puri PL Bai Y | 2005 | Mol Cell Biol2005，25，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员